<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00411515</url>
  </required_header>
  <id_info>
    <org_study_id>FR-2000-05-2006-06</org_study_id>
    <nct_id>NCT00411515</nct_id>
  </id_info>
  <brief_title>A Prospective Randomized Trial on Mycophenolate Mofetil in Risk Penetrating Keratoplasty</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Freiburg</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Freiburg</source>
  <brief_summary>
    <textblock>
      The purpose of this prospectively randomized multicentre study was to prove the efficacy and
      safety of mycophenolate mofetil (MMF) to preventing graft rejection and improvement of clear
      graft survival following high-risk keratoplasty.

      The patients of the MMF group receive MMF orally 2x1 g daily for 6 months. Endpoints were
      immune reaction free and clear graft survival and the occurence of side-effects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>Corneal Transplantation</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate Mofetil 2x 1g</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Keratoplasty with increased risk for immunologic graft rejection in the abscence of
             other risk factors for graft failure. (repeat keratoplasty, steroid-response,
             limbo-keratoplasty, oversized graft.

        Exclusion Criteria:

          -  Normal risk cases. Herpes-Keratitis. Glaucoma. Limbus stem cell deficiency.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Thomas Reinhard, Prof. MD</last_name>
    <role>Study Chair</role>
    <affiliation>University Eye Hospital, Freiburg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Eye hospital</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <results_reference>
    <citation>Reinhard T, Mayweg S, Sokolovska Y, Seitz B, Mittelviefhaus H, Engelmann K, Voiculescu A, Godehardt E, Sundmacher R. Systemic mycophenolate mofetil avoids immune reactions in penetrating high-risk keratoplasty: preliminary results of an ongoing prospectively randomized multicentre study. Transpl Int. 2005 Jun;18(6):703-8.</citation>
    <PMID>15910297</PMID>
  </results_reference>
  <verification_date>December 2006</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 12, 2006</study_first_submitted>
  <study_first_submitted_qc>December 12, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 14, 2006</study_first_posted>
  <last_update_submitted>December 14, 2006</last_update_submitted>
  <last_update_submitted_qc>December 14, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 15, 2006</last_update_posted>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycophenolic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

